drugset / Trial / NCT02472548
A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine
Phase 1
Completed
40 enrolled
Dalhousie University
ImmunoVaccine Technologies, Inc. (IMV Inc.) · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Administration of DPX-RSV(A), a Respiratory Syncytial Virus vaccine containing Respiratory Syncytial Virus (RSV) SHe antigen and DepoVaxTM adjuvant to healthy adults ≥50-64 years of age.
Timeline
- Start
- 2015-05
- Primary completion
- 2017-03-14
- Completion
- 2017-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DPX-RSV(A) | Peptide | — | Intramuscular |
| Subject | RSV(A)-Alum | Peptide | — | Intramuscular |